Alanine (L-Alanine)

Subscribe to Selected New Research on Alanine

2027 relevant articles (37 outcomes, 135 trials/studies) found for this Drug

Description: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.

Also Known As:

L-Alanine; Abufène; Alanine, L-Isomer; Doms-Adrian Brand of Alanine; Alanine Doms-Adrian Brand; Alanine, L Isomer; Doms Adrian Brand of Alanine; L Alanine; L-Isomer Alanine; (L)-Alanine

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

acetylalanine 4-nitroanilide: 19

lanthionine: 17

4-sulfoxyphenylacetyl dehydroalanine: 12

2-amino-3-phosphonopropionic acid: 10

FCE 26743: 10

dehydroalanine: 9

metalaxyl: 8

beta-(5-hydroxy-2-pyridyl)alanine: 6

N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide: 5

SQ 28603: 5

3-(phenylamino)alanine: 4

aladotril: 4

alaphosphin: 4

C(alpha)-formylglycine: 4

GS-9219: 4

N-ethylcarbaminomethyl-L-alanine: 4

alpha-naphthyl N-methoxycarbonylalaninate: 2

beta-methyllanthionine: 2

Lysinoalanine: 2

N,N'-((5-(2-amino-5-(2-methylpropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(alanine) diethyl ester: 2

N-(2-(mercaptomethyl)-3-phenylbutanoyl)-L-alanine: 2

N-(2-chloroethyl)-1-nitrosocarbamoylalanine: 2

N-myristoyl-alaninol: 2

RB 120: 2

(3-nitrobenzoyl)alanine: 1

1-(2-aminopyridin-4-ylmethyl)-6-(3,5-dimethylbenzoyl)-5-isopropyl-1H-pyrimidine-2,4-dione alanine amide: 1

2-((2'-amino)propionyl)aminobicyclo(3.1.0)hexane-2,6-dicarboxylic acid: 1

2-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-(3-methyl-4-oxo-4,5-dihydro-3H-benzo(d)(1,2)diazepin-5-yl)propanamide: 1

3-(2-naphthyl)alanine: 1

3-arsonoalanine: 1

3-fluoroalanine: 1

4-aminobenzoyl-alanine: 1

alanopine: 1

borotrimethylglycylphenylalanine: 1

dodecyl 2-(N,N-dimethylamino)propionate: 1

N-acetylalanyl-N-methylamide: 1

N-methylalanine: 1

OSU8 1: 1

oxindolealanine: 1

PPC amino acid preparation: 1

technetium 99m alafosfalin: 1

trienomycin A: 1

UBP 302: 1

willardiine: 1

(11-N-(benzyloxycarbonyl-alanyl)aminoundecanoyl)alanyl benzyl ester

(12-N-(benzyloxycarbonyl-alanyl)aminododecanoyl)alanyl benzyl ester

(2-(2,2,5,7,8-pentamethylchroman-6-sulphonyl)-indol-3-yl)alanine

(4-bromobenzyl)alanine ethyl ester

(6,7-dimethoxy-4-coumaryl)alanine

(9-acridinyl)alanine

(isoxazolin-5-on-2-yl)alanine

(R)-N-boc alaninal

1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropane

1-(2-amino-2-carboxyethyl)-3-(2-carboxy-5-phenylthiophene-3-ylmethyl)-5-methylpyrimidine-2,4-dione

1-(2-amino-2-carboxyethyl)-3-(2-carboxybenzyl)-5-iodopyrimidine-2,4-dione

1-(2-amino-2-carboxyethyl)-3-(2-carboxythiophene-3-ylmethyl)pyrimidine-2,4-dione

1-(3-(3-(aminoiminomethyl)phenyl)-2-((2-naphthalenylsulfonyl)amino)-1-oxopropyl)-4-methylpiperidine

1-alpha-amino-beta-chloropropionic acid hydroxamide

1-naphthylalanine

1-pyrenylalanine

2'-cyano-(biphenyl) alanine

2,2,6,6-tetramethyl-4--aminopiperidine-1-oxyl-N-(N'-(2-chloroethyl)nitrosocarbamoyl)alanine amide

2-(2-(5-bromoindan-1-yl)-3-mercaptopropionylamino)-3-(1H-pyrrolo(2,3-b)pyridin-3-yl)propionic acid

2-(alanylamino)-butyric acid

2-amino-2-(3-carboxycyclobutyl)-3-(9H-xanthen-9-yl)propionic acid

2-amino-2-(4-carboxyphenyl)-3-(9H-xanthen-9-yl)propanoic acid

2-amino-2-methyl-4-iodo-3-butenoic acid

2-amino-3,3'-difluoroisobutyric acid

2-amino-3-(1-(1,4,7-triazacyclononyl))propanoic acid

2-amino-3-(1-carbamimidoylpiperidin-3-yl)propanoic acid

2-amino-3-(3-(carboxymethoxy)-5-tert-butyl-4-isoxazolyl)propionic acid

2-amino-3-(3-carboxy-4-isoxazolyl)propionic acid

2-amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic acid

2-amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta(d)isoxazol-4-yl)propionic acid

2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid

2-amino-3-(4-hydroxy-1,2,5-thiadiazol-3-yl)propionic acid

2-amino-3-(5-(dimethylamino)naphthalene-1-sulfonamide)propanoic acid

2-amino-3-(5-tert-butyl-3-hydroxy-4-isothiazolyl)propionic acid

2-amino-3-(7-methoxy-4-coumaryl)propionic acid

Experts

1.	Good, Allen G: 2 articles (01/2008 - 03/2007)
2.	Miyashita, Yo: 2 articles (01/2008 - 03/2007)
3.	Castro, Eduardo A: 2 articles (04/2005 - 01/2004)
4.	Torrens, Francisco: 2 articles (04/2005 - 01/2004)
5.	Cheng, Suzanne: 2 articles (07/2004 - 05/2003)
6.	Cook, Nancy R: 2 articles (07/2004 - 05/2003)
7.	Erlich, Henry A: 2 articles (07/2004 - 05/2003)
8.	Zee, Robert Y L: 2 articles (07/2004 - 05/2003)
9.	Ridker, Paul M: 2 articles (07/2004 - 05/2003)
10.	Lindpaintner, Klaus: 2 articles (07/2004 - 05/2003)

Related Diseases

1.	Anoxia (Hypoxia) 04/01/1988 - "Alanine concentration in the plasma of fetuses subjected to hypoxia significantly increased within 24 h of exposure (0.28 +/- 0.10 vs 0.58 +/- 0.39 mmol/l; P less than 0.01) and remained elevated for the duration of the study. " 03/01/2008 - "It was concluded that the acceleration of alcohol fermentation and the accumulation of alanine were in favor of the enhancement of root zone hypoxia tolerance of cucumber roots." 03/01/2008 - "On the 8th day of hypoxia stress, the ADH activity and alcohol and alanine contents increased by 409.30%, 112.13% and 30.64% in Lübachun No. 4 roots and by 110.42%, 31.84% and 4.78% in Zhongnong No. 8 roots, respectively, compared with the control. " 07/01/2007 - "gigas PEPCK in muscle occurred at gene transcription level while PK was first regulated at enzyme level with alanine as allosteric inhibitor, and then at molecular level under a fast effect of hypoxia." 03/01/2007 - "The results showed that alaat1-1 plants accumulate more alanine than wild-type plants during the early phase of hypoxia, and the decline in accumulated alanine was delayed in the alaat1-1 line during the post-hypoxia recovery period. " Order ALL the reference details at left...
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/01/2002 - "Several studies have demonstrated an association of cytotoxic T lymphocyte-associated molecule 4 (CTLA-4) (IDDM 12) alanine 17 with type 1 diabetes, but we wished to study the parental effect of CTLA-4 49 A/G dimorphism in diabetic families. " 06/01/1991 - "The rate of alanine turnover was similar in the GDM and IDDM subjects and was not different from the normal subjects (GDM, 4.6 +/- 1.9; IDDM, 5.4 +/- 2.5; normals, 4.4 +/- 0.8 mumol/kg.min, mean +/- SD). " 08/01/1985 - "Insulin-dependent diabetes mellitus (IDDM) induces plasma amino acid (AA) abnormalities, including low alanine and high branched-chain (BCAA). " 02/01/1990 - "Increased hepatic efficacy of urea synthesis from alanine in insulin-dependent diabetes mellitus." 06/01/1991 - "In the present study, the effect of diabetes on alanine metabolism was examined in five gestationally diabetic (GDM) women and seven women with type I (insulin-dependent) diabetes (IDDM) during the third trimester of pregnancy. " Order ALL the reference details at left...
3.	Starvation 03/01/1969 - "It is concluded that the marked decrease in plasma alanine is due to augmented and preferential splanchnic utilization of this amino acid in early starvation resulting in substrate depletion. " 04/01/2004 - "Prolonged d-alanine starvation resulted in cells with an aberrant morphology. " 11/10/1994 - "Addition of alanine to the starvation medium led to detection of the 50 kDa form only. " 07/11/1993 - "In addition, the rate of labeled alanine metabolism was significantly reduced by starvation. " 07/11/1993 - "Metabolic fate of alanine in an insect Manduca sexta: effects of starvation and parasitism." Order ALL the reference details at left...
4.	Hepatitis B 03/01/2005 - "METHODS: In Japanese genotype C-dominant hepatitis B patients, 25 patients who stopped treatment at normal levels of alanine transferase (ALT) were retrospectively compared with 75 patients who continued treatment. " 11/01/2007 - "Those who are infected at adolescence or adulthood (including most of the Caucasians) tend to have stable disease after hepatitis B e antigen seroconversion with normal serum alanine aminotransaminase (ALT) and hepatitis B virus (HBV) DNA levels <10(5) copies/mL (20 000 IU/mL). " 06/01/1995 - "The significant elevation of serum alanine transferase (ALT) and bilirubin concentrations in sickle cell children denotes a process of mild hepatocellular dysfunction which is unrelated to hepatitis-B viral antigenaemia. " 10/01/1980 - "Transaminase values [alanine amino transferase (ALT) and aspartate amino transferase (AST)] and markers for hepatitis B were serially determined in 558 hemophiliacs exposed to blood products. " 09/01/1986 - "In an additional five patients with acute hepatitis B, serial serum samples, beginning before the serum alanine amino transferase elevation to the clearance of hepatitis B surface antigen, also were tested for various hepatitis B virus markers, including HBV-DNA. " Order ALL the reference details at left...
5.	Body Weight (Weight, Body) 07/01/2009 - "Donor hepatocytes engrafted into iMSUD recipient liver, increased liver BCKDH activity, improved blood total BCAA/alanine ratio, increased body weight at weaning, and extended the lifespan of HTx-treated iMSUD mice compared to phosphate-buffered saline (PBS)-treated and untreated iMSUD mice. " 06/01/1997 - "Next, on 3 trials, the rats were given 15 min access to 0.3 M l-alanine and then injected with LiCl (0.15 M, 1.33 ml/100 g body weight ip). " 08/01/2002 - "The correlation coefficient between total 13CO2 output over 15 min after L-[1-(13)C]alanine administration and liver weight/body weight was 0.902 (P < 0.0001). " 10/01/1999 - "The alanine-SDS electrophoretic method was employed to examine changes in the MHC composition of IF, PYR, CRU and SAR muscles with the ontogenetic growth of the toad from post-natal life (body weight < 1 g) to late adulthood (body weight 200-450 g). " 03/01/1994 - "Following an overnight fast, alanine was infused at a rate of 2 mmol/(h.kg body weight [BW]). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Glycine (Aminoacetic Acid)
2.	Aspartic Acid (Aspartate)
3.	Transferases
4.	Lactic Acid
5.	Valine (L-Valine)
6.	Serine (L-Serine)
7.	Glutamic Acid (Glutamate)
8.	Glutathione (Reduced Glutathione)
9.	ORALIT (ORS)
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Fluid Therapy (Oral Rehydration Therapy)
2.	Drug Therapy (Chemotherapy)
3.	Transplants (Transplant)
4.	Brachytherapy
5.	Magic

Best Treatments:
Research Summary Report
on Anoxia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1351 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>